CXCR1 and amyotrophic lateral sclerosis: In addition, inhibition of the PDGF-CC/PDGFRα axis has been shown to reduce BBB dysfunction, and has beneficial therapeutic effects in animal models of spinal cord injury (SCI) [11], multiple sclerosis (MS) [12], traumatic brain injury (TBI) [13], seizures [14] and amyotrophic lateral sclerosis (ALS) [15].